Navigation Links
Targeting tumor behavior may lead to new liver cancer drugs
Date:6/18/2009

COLUMBUS, Ohio Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior. The agents target multiple genes associated with that behavior at one time.

The researchers wanted to find agents that might reverse the gene changes associated with invasive liver cancer and perhaps stop liver tumors from spreading in the body. Such therapy could greatly improve patient survival, the researchers say.

The findings are published online in the journal Cancer.

"This is an exciting new way to find potentially useful anti-cancer agents," says principal investigator Dr. Tushar Patel, director of hepatology and a researcher with Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

"For nearly two decades, cancer drug discovery has sought agents that block a single molecular target or pathway," he says. "Our approach identifies agents that could potentially block tumor progression by striking multiple genes that are associated with a particular cancer-related behavior."

New drugs for liver cancer are needed because the disease is widespread worldwide. The most common type of liver cancer, hepatocellular carcinoma, causes 630,000 deaths every year worldwide, and the incidence is rising in many countries, including the United States.

Only one drug is presently approved for treating advanced liver cancer, Patel says. He notes that several new agents are in development for the disease, but each affects just one or another of the many processes that are altered in liver cancer cells.

"We believe that targeting a certain type of tumor behavior might be helpful for liver cancer because many different biochemical pathways in tumor cells can be involved. Most targeted agents affect only one pathway, so a combination of drugs may be needed. Alternatively, new age
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
2. Targeting the more lethal form of the cancer rhabdomyosarcoma
3. Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions.
4. Stem Cell Study Offers Hope for Targeting Tumors
5. Migraine prevention by targeting glutamate receptors?
6. Targeting oxidized cysteine through diet could reduce inflammation and lower disease risk
7. Deadly in Pink: New Report Warns Big Tobacco Has Stepped Up Targeting of Women and Girls
8. Targeting the protein AEG1 impairs human liver cancer growth in mice
9. Tobacco Companies Targeting Teens, Study Says
10. APIC 2009 Targeting Zero Initiative Offers Practical Tools, Evidence-Based Elimination Strategies to Prevent the Deadliest Healthcare-Associated Infections
11. Targeting Cancers Own Stem Cells to Fight Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Fatigue, lack of safety ... number of accidents in the workplace, according to ... articles highlight safety issues that contribute to the ... occur on the job annually, according to the ... explore "preventable workplace accidents." , Safety Issue: "Extended ...
(Date:7/10/2014)... July 10, 2014 Thousands of ... in Copenhagen this July 13-17 to reveal the ... world closer to breakthroughs in dementia science. The ... largest conference of its kind. , As part ... as a catalyst for generating new knowledge about ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Register to ... DataSite recently streamed the live webinar ‘Capitalizing on the ... from a group of several M&A experts in the ... the broader energy transaction marketplace. These experts shared their ... the deal market in this sector has been revitalized. ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... 10, 2014 Best Drug ... that having family close by during a stay ... whether or not the process is successful, has ... website at http://www.bestdrugrehabilitation.com/success-stories/ . , The new ... testimonials from several Best Drug Rehabilitation graduates who ...
Breaking Medicine News(10 mins):Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2
... the appointment of Terence M. O,Brien as its ... an in-depth national search for the position vacated ... in June. O,Brien will assume his new ... healthcare delivery system, which is comprised of a ...
... A system that can recognize human gestures could provide ... interact with computers. A related system for the able ... more realistic. The system is described in detail in ... Arts and Technology . , Manolya Kavakli of the ...
... you first notice a door handle, your brain has ... sees the handle, then it sends information to various ... out the details, such as color and the direction ... object is sent further along the various brain pathways, ...
... to outer space for help in their attempt to ... southern China. , Once the Three Gorges Dam is ... space to determine whether changing water conditions in Poyang ... the snails associated with the chronic disease that can ...
... option , , THURSDAY, Dec. 18 (HealthDay News) -- The ... Web site Thursday intended to make choosing a nursing ... The updated Nursing Home Compare site uses a five-star ... motels, to rank institutions nationwide. , "The old site ...
... Society has worked out new guidelines for the diagnosis ... Malignant melanoma is responsible for 90% of deaths from ... last 30 years and UV radiation is thought to ... , Claus Garbe of Tbingen University and his ...
Cached Medicine News:Health News:Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer 2Health News:Bon Secours Charity Health System Appoints Terence M. O'Brien as Chief Executive Officer 3Health News:Gesture recognition 2Health News:Study indicates how we make proper movements 2Health News:Watching water from space could aid disease prevention in China 2Health News:Watching water from space could aid disease prevention in China 3Health News:Government Launches Nursing Home Rating System 2Health News:Government Launches Nursing Home Rating System 3
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
... Farnsworth Dichotomous testing sets are designed to ... Farnsworth D15 test is used to separate ... The L'Anthony Desaturated test is much more ... deficiency from Normal. Both of these ...
... as easy as 1-2-3: just three simple steps ... with rapid information before they leave your office. ... the appropriate therapy; no more follow-up appointments or ... A Test is a rapid immunochromatographic assay for ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: